EP 4314012 A1 20240207 - IMMUNOMODULATORS
Title (en)
IMMUNOMODULATORS
Title (de)
IMMUNMODULATOREN
Title (fr)
IMMUNOMODULATEURS
Publication
Application
Priority
- US 202163165455 P 20210324
- US 2022021760 W 20220324
Abstract (en)
[origin: WO2022204412A1] The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
IPC 8 full level
C07K 7/08 (2006.01); A61K 38/10 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01)
CPC (source: EP KR US)
A61K 47/54 (2017.08 - EP KR); A61K 47/542 (2017.08 - EP KR US); A61K 47/548 (2017.08 - EP KR US); A61P 31/00 (2018.01 - KR); A61P 35/00 (2018.01 - EP KR); A61P 37/04 (2018.01 - KR); C07K 7/08 (2013.01 - EP); C07K 7/54 (2013.01 - KR US); A61K 38/00 (2013.01 - KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022204412 A1 20220929; CN 117157306 A 20231201; EP 4314012 A1 20240207; JP 2024512074 A 20240318; KR 20230160321 A 20231123; US 2024199701 A1 20240620
DOCDB simple family (application)
US 2022021760 W 20220324; CN 202280023007 A 20220324; EP 22721158 A 20220324; JP 2023558898 A 20220324; KR 20237035909 A 20220324; US 202218551319 A 20220324